- New Zealand
- /
- Food and Staples Retail
- /
- NZSE:GXH
Green Cross Health Full Year 2025 Earnings: EPS: NZ$0.11 (vs NZ$0.084 in FY 2024)
Green Cross Health (NZSE:GXH) Full Year 2025 Results
Key Financial Results
- Revenue: NZ$523.8m (up 3.9% from FY 2024).
- Net income: NZ$16.0m (up 33% from FY 2024).
- Profit margin: 3.1% (up from 2.4% in FY 2024). The increase in margin was driven by higher revenue.
- EPS: NZ$0.11 (up from NZ$0.084 in FY 2024).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Green Cross Health shares are down 2.4% from a week ago.
Risk Analysis
Don't forget that there may still be risks. For instance, we've identified 4 warning signs for Green Cross Health (1 is a bit concerning) you should be aware of.
New: Manage All Your Stock Portfolios in One Place
We've created the ultimate portfolio companion for stock investors, and it's free.
• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About NZSE:GXH
Green Cross Health
Provides health care and advice services to communities in New Zealand.
Good value with proven track record.
Market Insights
Weekly Picks

An Undervalued 3.3Moz Gold Project in Canada
QuantumScape: A Mispriced Deep‑Tech Inflection Point With Multi‑Billion‑Dollar Optionality

EU#8 - Anheuser-Busch InBev: Courage, Capital, and the Discipline to Build an Empire

The capitalist colossus that makes your parcels magically appear, powers half the internet, and knows your shopping habits.
Recently Updated Narratives
Bajaj Auto has seen a correction in its stock price after a strong rally, making it an attractive opportunity for investors.

Aussie’s Barton Gold, No Debt Miner with 1 Mill That Changes Everything

ASIC is a technology-differentiated E&S insurer compounding book value with a structurally improving combined ratio
Popular Narratives
NVIDIA will see a profit margin surge of 55% in the next 5 years

Analyst Commentary Highlights Microsoft AI Momentum and Upward Valuation Amid Growth and Competitive Risks

